American College of Obstetricians and Gynecologists Recommends Microarray Analysis as First-Line Genetic Testing
05 Diciembre 2013 - 5:00AM
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for
developmental disorders and cancer diagnostics, today announced
that the American College of Obstetricians and Gynecologists (ACOG)
has issued new guidelines indicating that chromosomal microarray
analysis (CMA) is now recommended as the first-line genetic test in
pregnancies showing fetal abnormalities on an ultrasound screen.
The ACOG guidelines also indicate that microarray testing is
recommended as the preferred genetic test to help identify the
cause of death in stillbirths and intrauterine fetal demise when
further cytogenetic analysis is desired because of its increased
likelihood of obtaining results and improved detection of causative
abnormalities.
CMA is a DNA-based method of prenatal genetic testing. Like the
conventional prenatal genetic test known as karyotyping, CMA can
identify major chromosomal defects such as Down syndrome. But CMA
can also find many other genetic defects that are too small to be
detected by karyotyping. Both CMA and karyotyping require testing
of fetal tissue obtained with chorionic villus sampling (CVS) or
amniocentesis.
"We believe this new guidance from ACOG recommending CMA as the
first-line test when an ultrasound reveals one or more major
fetal abnormalities is a significant milestone in the evolution of
genetic testing for fetal abnormalities, but one that we had
expected based on the clinical data from recently published
studies," said Mark McDonough, President and CEO. "Due to the
support of ACOG and its opinion leaders, we believe clinicians are
now more likely to counsel patients on the availability of
microarray testing and offer this option to them as a first-line
test. We believe ACOG's recognition of microarray testing's
increased likelihood of obtaining results and improved detection of
causative abnormalities in stillbirths and intrauterine fetal
demise also is an important milestone in those areas of care."
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic
solutions and comprehensive clinical support for the highest
quality of care – specializing in miscarriage analysis, prenatal
and pediatric healthcare. CombiMatrix offers comprehensive testing
services for the detection of genetic abnormalities at the DNA
level, beyond what can be identified through traditional
methodologies. The Company performs genetic testing utilizing
advanced technologies, including microarray, FISH, PCR and G-Band
chromosome analyses. Additional information about CombiMatrix is
available at www.combimatrix.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon our current expectations, speak only as of the date
hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," "expects,"
"intends," "plans," "goal," "predicts," "believes," "seeks,"
"estimates," "may," "will," "more likely to," "should," "would,"
"could," "potential," "continue," "ongoing," "objective," similar
expressions, and variations or negatives of these words and
include, but are not limited to, statements regarding the
advantages and efficacy of CMA over standard karyotyping, the
evolution of genetic testing for fetal abnormalities, stillbirths
and intrauterine fetal demise, and the likelihood that clinicians
will counsel patients on the availability of microarray testing and
offer it as a first-line test. These forward-looking
statements are not guarantees of future results and are subject to
risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in
any forward-looking statement. The risks and uncertainties
referred to above include, but are not limited to: market
acceptance of CMA as a preferred method over karyotyping; the rate
of transition to CMA from karyotyping; our ability to successfully
expand the base of our customers and strategic partners, add to the
menu of our diagnostic tests in both of our primary markets,
develop and introduce new tests and related reports, optimize the
reimbursements received for our testing services, and increase
operating margins by improving overall productivity and expanding
sales volumes; our ability to successfully accelerate sales, allow
access to samples earlier in the testing continuum, steadily
increase the size of our customer rosters in both developmental
medicine and oncology; our ability to attract and retain a
qualified sales force; rapid technological change in our markets;
changes in demand for our future products; legislative, regulatory
and competitive developments; general economic conditions; and
various other factors. Further information on potential
factors that could affect our financial results is included in our
Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in
other filings with the Securities and Exchange Commission. We
undertake no obligation to revise or update publicly any
forward-looking statements for any reason, except as required by
law.
CONTACT: Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
Tel (949) 753-0624
Media Contact:
Len Hall
VP, Media Relations
Allen & Caron
Tel (949) 474-4300
len@allencaron.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2024 a Jul 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024